Released on: January 7, 2008, 7:25 am

Press Release Author: Valerie Thomas

Industry: Biotech

Press Release Summary: Axium Healthcare Pharmacy announced today that it has been
awarded the clinical trial management contract for OxThera's OxabactT. OxabactT is
manufactured by OxThera.

Press Release Body: For Immediate Release
Contact: Valerie Thomas
Corporate Director of Marketing
(888) 315-3395
Valerie.thomas@axiumhealthcare.com

AXIUM HEALTHCARE PHARMACY AWARDED PHASE III
CLINICAL TRIAL MANAGEMENT CONTRACT FOR
OXTHERA'S OXABACTT

Lake Mary, Fla. (January 7, 2008) - Axium Healthcare Pharmacy, one of the nation's
largest independent specialty pharmacy providers, announced today that it has been
awarded the clinical trial management contract for OxThera's OxabactT. OxabactT is
manufactured by OxThera.

OxabactT is a capsulated bacterium that requires frozen storage and strict
refrigerated shipment monitoring. The indication for OxabactT is Primary
Hyperoxaluria (PH), a rare pediatric genetic disease, which causes the liver to
produce excess amounts of oxalate. The estimated U.S. population for PH is in the
range of 1,000 patients.

Axium will be working in conjunction with OxThera and the Mayo Clinic in this Phase
III clinical trial. "We are excited about the opportunity to be working with
OxThera in the drug management of their Phase III clinical trial for Oxabact. It
will also be an honor working on this project with the prestigious Mayo Clinic, said
Mark Montgomery, President & CEO of Axium."

Jon Heimer, President of OxThera, said, "OxThera is very excited about entering into
Phase III studies with OxabactT in the U.S. and look forward to collaborating with
Axium Healthcare Pharmacy for the important process of drug management."


About Axium Healthcare Pharmacy:

Axium Healthcare Pharmacy, Inc. is a nationwide clinical specialty pharmacy provider
with expertise in managing patients on complex therapies and specialty medication
distribution. As one of the nation\'s leading specialty pharmacies, Axium Healthcare
Pharmacy, Inc. provides comprehensive therapy-management programs as well as
injectable and oral pharmaceutical treatments for Hepatitis C, Multiple Sclerosis,
Cancer, Rheumatoid Arthritis, Growth Hormone Deficiency plus others. For more
information, contact Axium Healthcare Pharmacy at 888.315.3395; by email
info@axiumhealthcare.com


About OxThera:

OxThera is a clinical stage biotechnology company with its first product in Phase
III. The company is based in Sweden (Uppsala) and Florida (Gainesville). The company
develops products, based on its cell- and enzyme based proprietary technologies, for
metabolic disorders based on excess oxalate from endogenous and exogenous sources.
OxThera will market and sell its orphan drug products to treat and prevent
hyperoxaluria and kidney stones in indications such as Primary and Enteric
Hyperoxaluria. For more information, contact OxThera at (386) 418-1428; by email
info@oxthera.com.

Web Site: http://www.axiumhealthcare.com

Contact Details: Axium Healthcare Pharmacy, Inc.
550 Technology Park
Lake Mary, Florida 32746
Phone: 1-888-315-3395
Fax: 1-888-315-3270